Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropustine for poor platelet recovery after allogeneic hematopoietic stem cell transplantation
ChiCTR2600135061Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Nov 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of QL0911 in platelet engraftment failure, sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoint: Proportion of patients achieving complete remission based on platelet count. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
QL0911
03
Conditions
platelet engraftment failure
Beyond the preview
Go deeper on ChiCTR2600135061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135061.